A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Published:2012-11 Issue:11 Volume:23 Page:2834-2842
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kindler H.L.,Richards D.A.,Garbo L.E.,Garon E.B.,Stephenson J.J.,Rocha-Lima C.M.,Safran H.,Chan D.,Kocs D.M.,Galimi F.,McGreivy J.,Bray S.L.,Hei Y.,Feigal E.G.,Loh E.,Fuchs C.S.

Funder

Amgen Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/11/2834/13787715/mds142.pdf

Reference37 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

3. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer;Cunningham;J Clin Oncol,2009

4. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group;Poplin;J Clin Oncol,2009

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

2. MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer;Animal Cells and Systems;2024-04-30

3. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model;Cell Death Discovery;2024-03-29

4. Clinical immunotherapy in pancreatic cancer;Cancer Immunology, Immunotherapy;2024-03-02

5. Monoclonal Antibody Development for Cancer Treatment Using the Phage Display Library Platform;Biologics;2024-02-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3